Aldehyde tag coupled with HIPS chemistry enables the production of ADCs conjugated site-specifically to different antibody regions with distinct in vivo efficacy and PK outcomes

Bioconjugate Chemistry

Volumn 25, Issue 7, 2014, Pages 1331-1341

  Drake, Penelope M ^a   Albers, Aaron E ^a   Baker, Jeanne ^a   Banas, Stefanie ^a   Barfield, Robyn M ^a   Bhat, Abhijit S ^a   De Hart, Gregory W ^a   Garofalo, Albert W ^a   Holder, Patrick ^a   Jones, Lesley C ^a   Kudirka, Romas ^a   McFarland, Jesse ^a   Zmolek, Wes ^a   Rabuka, David ^a  

^a Redwood Bioscience Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALDEHYDES; AMINO ACIDS; MAMMALS; PHARMACOKINETICS;

A-STABLE; ANTIBODY-DRUG CONJUGATES; C-C BONDS; CONJUGATION CHEMISTRY; IN-VIVO; PROPERTY; SITE-SPECIFIC; SPECIFIC CONJUGATIONS; VIVO EFFICACIES; VIVO PHARMACOKINETICS;

ANTIBODIES;

ALDEHYDE; CYTOTOXIN; MONOCLONAL ANTIBODY; TRASTUZUMAB; ANTIBODY CONJUGATE; ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERBB2 PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; CHEMICAL BOND; CHEMICAL REACTION; CONJUGATION; CONTROLLED STUDY; DRUG HALF LIFE; HYDRAZINO ISO PICTET SPENGLER CHEMISTRY; IN VIVO STUDY; MOUSE; NONHUMAN; TUMOR XENOGRAFT; ANIMAL; BREAST NEOPLASMS; CELL PROLIFERATION; CHEMICAL STRUCTURE; CHEMISTRY; DRUG EFFECTS; DRUG SCREENING; FEMALE; HUMAN; IMMUNOLOGY; PATHOLOGY; RAT; SCID MOUSE; SPRAGUE DAWLEY RAT; STRUCTURE ACTIVITY RELATION; TISSUE DISTRIBUTION; TUMOR CELL CULTURE;

ALDEHYDES; ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CELL PROLIFERATION; FEMALE; HUMANS; IMMUNOCONJUGATES; MICE; MICE, SCID; MOLECULAR STRUCTURE; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, ERBB-2; STRUCTURE-ACTIVITY RELATIONSHIP; TISSUE DISTRIBUTION; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84904408813     PISSN: 10431802     EISSN: 15204812     Source Type: Journal    
DOI: 10.1021/bc500189z     Document Type: Article

References (34)

1. Sievers, E. L. and Senter, P. D. (2013) Antibody-drug conjugates in cancer therapy Annu. Rev. Med. 64, 15-29
2. Mullard, A. (2013) Maturing antibody-drug conjugate pipeline hits 30 Nat. Rev. Drug Discovery 12, 329-332
3. Panowksi, S., Bhakta, S., Raab, H., Polakis, P., and Junutula, J. R. Site-specific antibody drug conjugates for cancer therapy. mAbs 2014, 6.
4. Hamblett, K. J. 2004, Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate Clin. Cancer Res. 10, 7063-7070
5. Junutula, J. R. 2008, Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index Nat. Biotechnol. 26, 925-932
6. Strop, P. 2013, Location matters: site of conjugation modulates stability and pharmacokinetics of antibody drug conjugates Chem. Biol. 20, 161-167
7. Axup, J. Y. 2012, Synthesis of site-specific antibody-drug conjugates using unnatural amino acids Proc. Natl. Acad. Sci. U. S. A. 109, 16101-16106
8. Kung Sutherland, M. S., Walter, R. B., Jeffrey, S. C., Burke, P. J., Kostner, H. A., Stone, I., Ryan, M. C., Sussman, D., Lyon, R. P., Zeng, W., Harrington, K. H., Klussman, K., Westendorf, L., Meyer, D., Bernstein, I. D., Senter, P. D., Benjamin, D. R., Drachman, J. G., and McEarchern, J. A. (2013) SGN-CD33A: a novel CD33-targeting antibody-drug conjugate using a pyrrolobenzodiazepine dimer is active in models of drug-resistant AML Blood 122, 1455-1463
9. Rabuka, D., Rush, J. S., deHart, G. W., Wu, P., and Bertozzi, C. R. (2012) Site-specific chemical protein conjugation using genetically encoded aldehyde tags Nat. Protoc. 7, 1052-1067
10. Carlson, B. L. 2008, Function and structure of a prokaryotic formylglycine-generating enzyme J. Biol. Chem. 283, 20117-20125
11. Sletten, E. M. and Bertozzi, C. R. (2009) Bioorthogonal chemistry: fishing for selectivity in a sea of functionality Angew. Chem., Int. Ed. Engl. 48, 6974-6998
12. Agarwal, P. 2013, Hydrazino-Pictet-Spengler ligation as a biocompatible method for the generation of stable protein conjugates Bioconjugate Chem. 24, 846-851
13. Tian, F. 2014, A general approach to site-specific antibody drug conjugates Proc. Natl. Acad. Sci. U. S. A. 111, 1766-71
14. Shen, B.-Q. 2012, Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates Nat. Biotechnol. 30, 184-189
15. Ramsland, P. A. and Farrugia, W. (2002) Crystal structures of human antibodies: a detailed and unfinished tapestry of immunoglobulin gene products J. Mol. Recognit. 15, 248-259
16. Bryson, C. J., Jones, T. D., and Baker, M. P. (2010) Prediction of immunogenicity of therapeutic proteins: validity of computational tools BioDrugs 24, 1-8
17. Perry, L. C. A., Jones, T. D., and Baker, M. P. (2008) New approaches to prediction of immune responses to therapeutic proteins during preclinical development Drugs R & D 9, 385-396
18. LoRusso, P. M., Weiss, D., Guardino, E., Girish, S., and Sliwkowski, M. X. (2011) Trastuzumab emtansine: a unique antibody-drug conjugate in development for human epidermal growth factor receptor 2-positive cancer Clin. Cancer Res. 17, 6437-6447
19. Girish, S. 2012, Clinical pharmacology of trastuzumab emtansine (T-DM1): an antibody-drug conjugate in development for the treatment of HER2-positive cancer Cancer Chemother. Pharmacol. 10.1007/s00280-011-1817-3
20. Junttila, T. T., Li, G., Parsons, K., Phillips, G. L., and Sliwkowski, M. X. (2011) Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer Breast Cancer Res. Treat. 128, 347-356
21. Roopenian, D. C. and Akilesh, S. (2007) FcRn: the neonatal Fc receptor comes of age Nat. Rev. Immunol. 7, 715-725
22. Wang, W. 2011, Monoclonal antibodies with identical Fc sequences can bind to FcRn differentially with pharmacokinetic consequences Drug Metab. Dispos. 39, 1469-1477
23. Jones, T. D. 2005, Identification and removal of a promiscuous CD4+ T cell epitope from the C1 domain of factor VIII J. Thromb. Haemost. 3, 991-1000
24. Jones, T. D. 2004, The development of a modified human IFN-alpha2b linked to the Fc portion of human IgG1 as a novel potential therapeutic for the treatment of hepatitis C virus infection J. Interferon Cytokine Res. 24, 560-572
25. Baker, M. P. and Jones, T. D. (2007) Identification and removal of immunogenicity in therapeutic proteins Curr. Opin Drug Discov Devel 10, 219-227
26. Ritter, G. 2001, Serological analysis of human anti-human antibody responses in colon cancer patients treated with repeated doses of humanized monoclonal antibody A33 Cancer Res. 61, 6851-6859
27. Scott, A. M. 2005, A phase I trial of humanized monoclonal antibody A33 in patients with colorectal carcinoma: biodistribution, pharmacokinetics, and quantitative tumor uptake Clin. Cancer Res. 11, 4810-4817
28. Welt, S. 2003, Phase I study of anticolon cancer humanized antibody A33 Clin. Cancer Res. 9, 1338-1346
29. Poon, K. A. 2013, Preclinical safety profile of trastuzumab emtansine (T-DM1): Mechanism of action of its cytotoxic component retained with improved tolerability Toxicol. Appl. Pharmacol. 273, 298-313
30. Carrico, I. S., Carlson, B. L., and Bertozzi, C. R. (2007) Introducing genetically encoded aldehydes into proteins Nat. Chem. Biol. 3, 321-322
31. Boswell, C. A. 2011, Impact of drug conjugation on pharmacokinetics and tissue distribution of Anti-STEAP1 antibody-drug conjugates in rats Bioconjugate Chem. 22, 1994-2004
32. Jackson, D. 2014, In vitro and in vivo evaluation of cysteine and site specific conjugated herceptin antibody-drug conjugates PLoS One 9, e83865
33. Lewis Phillips, G. D. 2008, Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate Cancer Res. 68, 9280-9290
34. Bleck, G. T. (2007) An alternative method for the rapid generation of stable, high-expressing mammalian cell lines BioProcess. J. 5, 36